Business
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatment Financing also drives early- and late-stage clinical execution of diverse pipeline spanning multiple therapeutic areas COMMACK, NY, May 07, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enh
About this update from Scienture Holdings, Inc.
[{"type":"image","alt":"Scienture Holdings, Inc.","displaySize":"","headline":null,"caption":"Scienture Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/0f6cc02a4da7ea464abfe1cb57925027"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HVe91D1EZWtbCkMx1Lfv7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2/https://media.zenfs.com/en/globenewswire.com/0f6cc02a4da7ea464abfe1cb57925027","width":300,"height":33},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/HVe91D1EZWtbCkMx1Lfv7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2/https://media.zenfs.com/en/globenewswire.com/0f6cc02a4da7ea464abfe1cb57925027","width":300,"height":33}},"lazy":false},{"type":"text","content":"Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatment","length":178,"tagName":"p"},{"type":"text","content":"Financing also drives early- and late-stage clinical execution of diverse pipeline spanning multiple therapeutic areas ","length":118,"tagName":"p"},{"type":"text","content":"COMMACK, NY, May 07, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has secured $11 million in non-dilutive debt financing through a note purchase agreement with an institutional investor. In connection with the note purchase agreement, the Company issued two non-convertible promissory notes: (i) a promissory note in the original principal amount of $8.42 million and (ii) a secured promissory note in the original principal amount of $3 million, together providing approximately $11 million in net proceeds to the Company. Additional information regarding the transaction is included in the Company’s Form 8-K filed with the Securities and Exchange Commission on May 1, 2026.","length":995,"tagName":"p"},{"type":"text","content":"“This non-dilutive financing provides us with additional capital to execute on our critical strategic initiatives, including the continued scaling of our commercial...